American Academy of Optometry

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Retrieved on: 
Thursday, November 9, 2023
DB, Food, Eyelid, MITES, Disease, American Academy, Patient, PPP, ECP, FDA, Science, Optometry, TARS, American Academy of Optometry, American Academy of Ophthalmology, PDUFA, Pharmaceutical industry, Demodex, Ophthalmology

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.

Key Points: 
  • Management to host conference call today, November 9, 2023, at 1:30 p.m. P.T.
  • IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.
  • Saturn-2 data were delivered as encore presentations at the American Academy of Optometry and American Academy of Ophthalmology conferences.
  • In the third quarter of 2023:
    The Company’s expansive disease education efforts continue to drive awareness among eye care providers (ECPs) and action in proactively diagnosing DB.

Wilmington Community Rallies for first Dry Eye Fundraiser

Retrieved on: 
Tuesday, December 12, 2023
Television, Telecanthus, Research, HOPE, Lecture, American Academy, Southern College of Optometry, Patient, Multimedia, Fellow, Science, Dry eye syndrome, Tears, Bloom, Brimer, American Academy of Optometry, Publishing, Physician, Quality of life, Ophthalmology, Hospital

Dry eye disease affects millions of people, causing discomfort, vision disturbances, and sometimes severe complications if left untreated.

Key Points: 
  • Dry eye disease affects millions of people, causing discomfort, vision disturbances, and sometimes severe complications if left untreated.
  • With the support of our generous community, we can make a significant impact on the lives of those affected by Dry Eye Disease."
  • She owns a specialty eye clinic, the Dry Eye Equation, in Wilmington, NC, and is dedicated to treating patients with an innovative, personalized approach.
  • For more than two decades, Dr. Brimer has spent her career advancing the science of diagnosing and treating dry eye disease.

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

Retrieved on: 
Monday, October 30, 2023
FDA, Refractive surgery, Optometry, Tropicamide, Joint Commission on Allied Health Personnel in Ophthalmology, Presbyopia, ACE, Inflammation, Phenylephrine, American Academy, International Joint Commission, American Academy of Ophthalmology, American Academy of Optometry, Allied health professions, Somatosensory system, Mydriasis, Pain, Pharmaceutical industry, Ophthalmology

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP130007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it is sponsoring a course during the International Joint Commission on Allied Health Personnel in Ophthalmology (IJCAHPO) 51st Annual Continuing Education (ACE) program, which is being held November 3-5 in San Francisco.

Key Points: 
  • The course, Topical Pharmaceutical Drug Delivery Innovations: The Potential Role for the New Ophthalmic Spray, will offer ophthalmic technicians background on Eyenovia’s Optejet dispensing technology and training on the use of Mydcombi in daily practice.
  • “We continue to ramp our internal manufacturing capabilities, staff our sales management team and obtain additional key state licenses of which we now have eight either completed or in process.
  • We look forward to transitioning to a broader commercial launch of Mydcombi in early 2024.”
    Topical Pharmaceutical Drug Delivery Innovations: The Potential Role for the New Ophthalmic Spray
    Francis Mah, M.D., Director of Cornea and External Disease and the Co-Director, Refractive Surgery at Scripps Clinic.
  • In addition, Mydcombi was featured in a white paper on Touch Ophthalmology, Pharmacologic Mydriasis and Cycloplegia: A Review of Novel Delivery Devices, which can be accessed here .

Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program

Retrieved on: 
Thursday, October 12, 2023
Antibody, American Academy of Ophthalmology, Eye, American Academy, Tears, RESEARCH, American Academy of Optometry, Therapy, Vitamin A, Research Triangle, PARK, Blood, Patient, Pharmaceutical industry, Telescopic sight

RESEARCH TRIANGLE PARK, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Biotechnology innovator Merakris Therapeutics has unveiled a unique program that delivers personalized autologous serum tears—in less than 2 hours—without patients ever having to leave home.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Biotechnology innovator Merakris Therapeutics has unveiled a unique program that delivers personalized autologous serum tears—in less than 2 hours—without patients ever having to leave home.
  • The Opticyte® Tears program uses patients’ own blood serum to create Opticyte Autologous Serum Tears from the convenience of their homes or an optical provider’s office.
  • The Opticyte Tears program delivers unmatched convenience and time saving advantages, combined with consumer-friendly packaging, according to Merakris CEO Chris Broderick.
  • As soon as a clinician submits a request for Opticyte Tears, Merakris contacts the patient to schedule an at-home or in-clinic visit by a specialist.

VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting

Retrieved on: 
Thursday, October 12, 2023
Medical Supplies, Health, Medical Devices, Consumer, Children, Clinical Trials, Optical, Food, American Academy, ASX, VTI, American Academy of Optometry, Safety, Interim, Clinical trial, Per, Near-sightedness, Protocol, Contact, PROTECT, Regulation of tobacco by the U.S. Food and Drug Administration, RCT, Contact lens, Patient, Medical device, Optometry

Visioneering Technologies, Inc. (ASX:VTI), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, presented interim data from the PROTECT Clinical Trial at the American Academy of Optometry's annual meeting.

Key Points: 
  • Visioneering Technologies, Inc. (ASX:VTI), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, presented interim data from the PROTECT Clinical Trial at the American Academy of Optometry's annual meeting.
  • Interim 1-year data from the PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) clinical trial, conducted across four countries, demonstrated the safety and effectiveness of NaturalVue Multifocal (“NVMF”) contact lenses in controlling myopia progression in pediatric patients.
  • Over 12 months, the treatment effect yielded a 69% (0.41Diopter) reduction in refractive error compared to the control group.
  • We're thrilled to unveil the 1-year interim results of our PROTECT RCT, demonstrating the effectiveness of NaturalVue Multifocal in managing myopia in children."

Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia

Retrieved on: 
Tuesday, October 10, 2023
General Health, Health, Optical, Lens, NYSE, American Academy, Prevalence, Innovation, Water, OD, Astigmatism, AIR, American Academy of Optometry, Sphere, Contact, Patient, Presbyopia, Reading, Camera, Telescopic sight, Alcon

Data show 96% of patients were successfully fit in Alcon multifocal contact lenses with the PRECISION PROFILE optical design.2-4

Key Points: 
  • Data show 96% of patients were successfully fit in Alcon multifocal contact lenses with the PRECISION PROFILE optical design.2-4
    “Multifocal contact lenses have been a key source of customers and referrals for my practice,” said Jessica Crooker, OD.
  • “Many patients are simply unaware that there are multifocal contact lens options.
  • So, when I introduce them to Alcon’s multifocal lenses, they’re thrilled to have their vision without having to rely on over-the-counter reading glasses.” Dr. Crooker adds, “Now, with TOTAL30 Multifocal, along with DAILIES TOTAL1 Multifocal, I’m delighted to offer my patients a monthly replacement and daily disposable contact lens option with the exceptional comfort of Water Gradient Technology.”1
    TOTAL30 portfolio also includes TOTAL30 Sphere lenses and TOTAL30 for Astigmatism.
  • Alcon will debut TOTAL30 Multifocal contact lenses during the American Academy of Optometry conference on October 11-14 in New Orleans, Louisiana.

Dry Eye Foundation Launches New Eye Drop Lookup Tool

Retrieved on: 
Thursday, October 12, 2023
Food, Hope, Eye, American Academy, Food and Drug Administration Amendments Act of 2007, American Academy of Optometry, Safety, Patient, FDA, Education, Optometry, Confusion, Research, Quality of life, Pharmaceutical industry

NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- Dry Eye Foundation announced the launch of an easy-to-search eye drop database called "Are My Eye Drops Safe?" today during the American Academy of Optometry's annual meeting. Health care professionals and consumers can use this tool to find detailed information on over-the-counter eye drops sold in the US, including illegally marketed products, recalled products, and products subject to FDA safety communications or warnings.

Key Points: 
  • NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- Dry Eye Foundation announced the launch of an easy-to-search eye drop database called "Are My Eye Drops Safe?"
  • "We built this tool to help get people access to real-time information on eye drop safety and cut through the confusion."
  • The Dry Eye Foundation is a 501(c)(3) nonprofit organization based in Poulsbo, Washington.
  • Dry Eye Foundation is working to restore hope, redefine disease and reshape the future for people with these conditions, through its community service, education, research and advocacy programs.

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

Retrieved on: 
Thursday, July 20, 2023
American Academy of Optometry, RCT, Eye disease, American Academy, Wills Eye Hospital, Gland, OSDI, Telecanthus, Optometry, Patient, Physician, Randomized controlled trial, Entrepreneurship, Principal, Bias, MGD, Pharmaceutical industry, Medical imaging, MD, Ciclosporin

The trial successfully met its primary endpoint and the data reported statistically significant improvements as compared to Restasis eye drops for the treatment of dry eye disease.

Key Points: 
  • The trial successfully met its primary endpoint and the data reported statistically significant improvements as compared to Restasis eye drops for the treatment of dry eye disease.
  • The SAHARA trial also observed that procedures enabled by TearCare were non-inferior to Restasis eyedrops in Ocular Surface Disease Index (OSDI), which was the co-primary six-month endpoint.
  • Symptoms endpoints include two commonly used patient-reported questionnaires: Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE).
  • Sight Sciences designed its TearCare technology and its comprehensive interventional eyelid procedure to safely and effectively treat the underlying obstructive causes of MGD.

Pinakin Davey, OD, PhD, FAAO, FARVO, Joins EyePromise® as Chief Medical & Science Officer

Retrieved on: 
Thursday, June 22, 2023
Health, Fitness & Nutrition, Other Science, Research, Science, Vitamins, Supplements, Optical, OGS, Glaucoma, American Optometric Association, ARVO, University, AAO, Macular degeneration, Doctor of Philosophy, Australian College of Optometry, Western University, Southern College of Optometry, AOA, Anglia Ruskin University, Patient, American Academy of Optometry, Outline of health sciences, Association for Research in Vision and Ophthalmology, University of Louisville School of Medicine, ZX, Western University of Health Sciences, Nursing, Optometry, Ophthalmology

EyePromise, the leading provider of evidence-based nutritional supplements for eye health, is pleased to announce the appointment of Dr. Pinakin Davey as its new Chief Medical & Science Officer.

Key Points: 
  • EyePromise, the leading provider of evidence-based nutritional supplements for eye health, is pleased to announce the appointment of Dr. Pinakin Davey as its new Chief Medical & Science Officer.
  • As the Chief Medical & Science Officer, Dr. Davey will play a pivotal role in shaping and driving EyePromise’s scientific and medical initiatives.
  • Dr. Pinakin Davey will also remain in his current position as a tenured Professor at Western University of Health Sciences, College of Optometry.
  • "We are thrilled to welcome Dr. Davey to EyePromise as our Chief Medical & Science Officer," said Andreas Wolf, President of EyePromise.

Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months

Retrieved on: 
Thursday, December 8, 2022
Duane syndrome, Data collection, OD, Patient, ECP, IIT, MGE, American Academy of Optometry, Roger Hawkins (drummer), MGD, American Academy, SPEED, Pharmaceutical industry, Optometry

Patients throughout the study exhibited improved dry eye signs and symptoms for more than 12 months, and in some cases up to 18 months, post treatment.

Key Points: 
  • Patients throughout the study exhibited improved dry eye signs and symptoms for more than 12 months, and in some cases up to 18 months, post treatment.
  • This data should help provide both patients and practitioners with confidence that a single TearCare® treatment may improve a patient’s dry eye symptoms for substantive period of time after the procedure is performed,” said Thomas Chester, OD, FAAO.
  • Patients’ symptoms were assessed at a single time point pre-treatment and at four time points post-treatment (8-12 weeks, 6 months, 12 months, and 18 months).
  • Results of the trial showed most subjects experienced at least 12 months of gland function improvement and decreased symptoms.